May 3 (Reuters) - Repare Therapeutics Inc RPTX.O :
* REPARE THERAPEUTICS DOSES FIRST PATIENT IN PHASE 1 CLINICAL TRIAL OF RP-6306, A FIRST-IN-CLASS, SELECTIVE, ORAL INHIBITOR OF PKMYT1
May 3 (Reuters) - Repare Therapeutics Inc RPTX.O :
* REPARE THERAPEUTICS DOSES FIRST PATIENT IN PHASE 1 CLINICAL TRIAL OF RP-6306, A FIRST-IN-CLASS, SELECTIVE, ORAL INHIBITOR OF PKMYT1